文献速递自身炎症与 IgG4 相关病其他结缔组织病

人单核细胞模型揭示VEXAS综合征基因型依赖性炎症程序

Human Monocytic Models Reveal Genotype-Dependent Inflammatory Programs in VEXAS Syndrome.
PubMed 文献 · Arthritis Rheumatol · 2026-09-07

OBJECTIVE: VEXAS syndrome is a severe X-linked autoinflammatory disorder caused by somatic mutations in ubiquitin-like modifier activating enzyme 1 (UBA1), with clinical outcomes that vary by UBA1 genotype.…

要点

  • UBA1突变单核细胞系呈现基因型分级依赖性泛素化缺陷与炎症表型。
  • RNASE1与VEXAS疾病活动度纵向相关(r=0.70,FDR<0.05)。
  • 抑制RIPK3可减轻所有病理特征,包括RNASE1上调。

核心结论

  • UBA1突变单核细胞系模型重现基因型依赖性炎症表型,且可被RIPK3抑制所调节,为VEXAS精准治疗提供转化平台。

研究设计与样本

  • 构建携带p.Met41Val、p.Met41Thr或p.Met41Leu三种主要UBA1突变的单核细胞系,进行转录组与功能分析。

主要发现

  • VEXAS综合征上调基因中RNASE1与纵向疾病活动度相关性最强(r=0.70,FDR<0.05),且在患者单核细胞中上调。
  • UBA1突变单核细胞系在无外源刺激下呈现分级性泛素化缺陷(p.Met41Val > p.Met41Thr > p.Met41Leu)。
  • 上述缺陷伴随未折叠蛋白反应激活、促炎细胞因子产生增加、进行性细胞死亡及RNASE1上调,呈相同分级模式。
  • 转录组分析显示更严重基因型中富集促炎、干扰素及坏死性凋亡特征。
  • 抑制RIPK3显著减轻所有病理特征,包括RNASE1上调。

临床怎么用

  • RNASE1可作为VEXAS疾病活动度的潜在纵向生物标志物。
  • RIPK3抑制是VEXAS综合征的潜在治疗靶点,尤其针对重症基因型。

局限性

  • 研究基于细胞系模型,尚未在临床治疗中验证RIPK3抑制的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: VEXAS syndrome is a severe X-linked autoinflammatory disorder caused by somatic mutations in ubiquitin-like modifier activating enzyme 1 (UBA1), with clinical outcomes that vary by UBA1 genotype. We aimed to elucidate genotype-specific inflammatory programs and identify potential therapeutic targets. METHODS: We conducted longitudinal deep phenotyping, including whole blood RNA sequencing (RNA-seq) and clinical activity assessment. Peripheral blood samples were analyzed by single-cell RNA-seq. Human monocytic cell lines harboring each major UBA1 mutation (p.Met41Val, p.Met41Thr, or p.Met41Leu) were generated and subjected to transcriptomic and functional analyses. RESULTS: Thirteen patients with VEXAS syndrome contributed a total of 79 RNA-seq samples. Among genes up-regulated in VEXAS syndrome, RNASE1 showed the strongest correlation with longitudinal disease activity (r = 0.70, false discovery rate < 0.05) and was up-regulated in patients' monocytes. In UBA1-mutant monocytic cell lines, genotype-dependent ubiquitination defects were observed in a graded manner (p.Met41Val > p.Met41Thr > p.Met41Leu), even in the absence of exogenous stimuli. These defects were accompanied by unfolded protein response activation, increased pro-inflammatory cytokine production, progressive cell death, and RNASE1 up-regulation, all following the same graded pattern of recapitulating patient genotype-phenotype associations. Transcriptomic analyses demonstrated enrichment of pro-inflammatory, interferon, and necroptosis signatures in more severe genotypes. Notably, inhibition of receptor-interacting protein kinase 3 (RIPK3) markedly attenuated all pathologic features, including RNASE1 up-regulation. CONCLUSION: Our UBA1-mutant monocytic cell-line models, representing three distinct genotypes, recapitulate genotype-dependent inflammatory phenotypes that can be modulated by RIPK3 inhibition, providing a translational platform for mechanistic investigation and precision therapy development in VEXAS syndrome.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Higashitani K, Ban T, Kirino Y, et al. Human Monocytic Models Reveal Genotype-Dependent Inflammatory Programs in VEXAS Syndrome. Arthritis Rheumatol. 2026. PMID: 42703964. doi:10.1002/art.70332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。